• It is unclear if platelet micro-RNAs can regulate de novo protein synthesis of platelets.
Essentials
• It is unclear if platelet micro-RNAs can regulate de novo protein synthesis of platelets.
• Platelet de novo protein synthesis of thrombospondin-1 (TSP-1) was induced by thrombin.
• Thrombin stimulation in vitro altered platelet micro-RNA profiles, including decreased miR-27b.
• Decreased miR-27b hampers platelet angiogenic activities via enhancing de novo TSP-1 synthesis.
Summary. Background: Platelets can synthesize proteins upon activation. Platelets contain a number of microRNAs (miRNA) and a fully functional miRNA effector machinery. It is, however, unclear if platelet miRNAs can regulate protein synthesis of platelets, and whether the regulation may produce a physiological impact. Objectives: To investigate if and how platelet miRNAs regulate de novo syntheses of angiogenic regulators and subsequently modulate platelet angiogenic activities. Methods and Results: Microarray-based miRNA profiling showed that thrombin stimulation in vitro down-or up-regulated a number of platelet miRNAs, both in the total platelet miRNAs and in Ago2-associated miRNAs. Among those altered miRNAs, miR-27b was down-regulated in both the total and Ago2-immunoprecipitated miRNA profiles of platelets, which was confirmed by reverse transcription-quantitative PCR (RT-qPCR). Using western blotting assays, we showed that thrombin induced platelet de novo synthesis of thrombospondin-1, and that the level of thrombospondin-1 synthesis could reach a level of 3-5-fold higher than that before thrombin stimulation. With either the platelet precursor megakaryocyte cell line MEG-01 cells or mature platelets, we demonstrated that transfection of miR-27b mimic, but not the negative control of miRNA mimic, markedly reduced thrombospondin-1 protein levels. The latter subsequently enhanced platelet-dependent endothelial tube formation on matrigel. Conclusions: Thrombin stimulation in vitro reduces platelet miR-27b levels that may markedly enhance thrombin-evoked platelet de novo synthesis of thrombospondin-1. Elevation of platelet miR-27b by transfection inhibits thrombospondin-1 synthesis, and subsequently enhances platelet pro-angiogenic activities. Hence, platelet activation-dependent reduction of miR27b levels may represent a novel negative regulatory mechanism of platelet angiogenic activities.
Introduction
Platelets play key roles in hemostasis and thrombosis, and are also a versatile player in inflammation, tissue regeneration, angiogenesis and cancer progression [1, 2] . Among other things, platelets exert their diverse physiological and pathophysiological functions via their rich storage and rapid release of granule content. Platelet a-granules contain a large number of peptides and proteins, mainly by inheriting from megakaryocytes (e.g., platelet factor 4) or active up-taking from plasma (e.g. fibrinogen). Anucleated platelets are traditionally considered as a cell type unable to synthesize proteins. However, accumulating evidence demonstrates that platelets are capable of synthesizing proteins [3] [4] [5] [6] [7] [8] . Platelets retain cytoplasmic mRNAs and maintain functionally intact protein translational machineries inherited from their megakaryocytic precursors. Upon activation, platelets exert de novo protein synthesis of, for example, interleukin-1b (IL-1b) [5] , plasminogen activator inhibitor-1 (PAI-1) [6] , thrombospondin-1 (TSP-1) [9] and stromal cell-derived factor-1a (SDF-1a) [10] . Platelets are rich in microRNAs (miRNAs) [11] [12] [13] . Platelets also harbour the key cytoplasmic components of miRNA effector complexes (Dicer and Ago2), suggesting that miRNA plays an important role in the gene regulatory network in platelets [14, 15] . Earlier reports have shown that platelets can release miRNAcontaining platelet-derived microvesicles, which can be up-taken by and subsequently regulate the protein synthesis and function of other cells, such as endothelial cells, cancer cells and smooth muscle cells [16] [17] [18] . A recent report shows that Dicer1-dependent generation of mature platelet miRNAs can regulate platelet mRNA profiles and protein synthesis [19] . It is therefore interesting to investigate if platelet miRNAs may regulate activation-dependent de novo platelet protein synthesis. Therefore, we asked if platelet activation would result in an altered platelet miRNA profile, if altered platelet miRNAs could regulate de novo protein synthesis of angiogenic factors in activated platelets, and even more importantly, if miRNA-regulated platelet angiogenic factor synthesis could result in changes of platelet angiogenic activities. Indeed, we found that thrombin stimulation down-or up-regulated a number of platelet miRNAs, and that miR-27b was down-regulated in both the total and Ago2-immunoprecipitated miRNA profiles of platelets. Furthermore, we demonstrated that platelet activation led to marked de novo synthesis of TSP-1, and that elevated miR-27b by miR-27b mimic transfection diminished TSP-1 synthesis in both the megakaryocyte cell line MEG-01 cells and mature platelets, which resulted in enhanced platelet angiogenic activities. Our findings imply that decreased miR-27b hampers the negative regulatory mechanism of TSP-1 synthesis, and exaggerates de novo synthesis of TSP-1 in activated platelets. The sequential reactions may represent a novel regulatory mechanism of platelet angiogenic activities.
Methods and materials

Study subjects
Thirty-two healthy volunteers (24 male, eight female; aged between 22 and 52 years) gave informed consent to participate in this study, which was approved by the Ethics Committee of Karolinska Institutet.
Reagents
Prostaglandin E 1 (PGE 1 ), a-thrombin and DMEM culture medium were from Sigma-Aldrich (St. Louis, MO, USA). CD45 Dynabeads and Dynabeads Ò Protein G were from Invitrogen (Carlsbad, CA, USA). Flow cytometric antibodies used were fluorescein isothiocyanate (FITC)-CD42a, phycoerythrin (PE)-CD41a, PE-CD62P and PE-CD45 (all from Becton Dickinson, San Jose, CA, USA). The anti-Ago2 antibody ab57113 for immunoprecipitation was from Abcam (Cambridge, UK). TaqMan microRNA Reverse Transcription Kit, mirVana TM miR27b mimic and miRNA negative control #1 were from Applied Biosystems (Austin, TX, USA). Human TSP-1 antibody was from R&D Systems (Abingdon, UK).
Platelet preparation and stimulation
Citrated venous blood was centrifuged at 190 9 g for 20 min at 22°C, and the upper two-thirds of platelet-rich plasma (PRP) was collected. After adding PGE 1 (final concentration 1 lM), PRP was re-centrifuged at 190 9 g for 10 min. Again, the top two-thirds of PRP was collected to reduce leukocyte contamination. Platelets were further purified by leukocyte depletion using CD45 Dynabeads. Afterwards, PRP was washed with Tyrode's HEPES buffer containing 1 lM PGE 1 , and centrifuged at 1000 9 g for 10 min. Platelets were then resuspended in DMEM medium at 10 9 mL
À1
, and kept on a bench for 30 min to allow the recovery of platelet responsiveness. The present platelet-isolating protocol conferred a leukocyte contamination rate less than 0.0001%, as assessed by flow cytometry.
Purified platelets were treated with vehicle or thrombin (0.1 U mL
) at 37°C for 30 min. For the samples used to demonstrate de novo protein synthesis, unstimulated and thrombin-stimulated platelets were centrifuged at 1000 9 g after 30 min incubation. The supernatant was removed to avoid re-uptake of released proteins by platelets, and platelet pellets were re-suspended with the same volume of DMEM medium without fetal bovine serum (FBS). The samples were further cultured at 37°C for 2 or 24 h.
Culture of endothelial progenitor cells (EPCs)
EPCs were generated as previously described [20] by culturing peripheral blood mononuclear cells in EGM-2 SingleQuots complete medium (EBM-2 basal medium, 10% FBS, and the SingleQuots Kit).
Flow cytometry
Flow cytometric analyses were performed as previously described [21] . Platelet gating was confirmed by FITCCD42a staining (> 98% positive). Platelet activation was monitored by P-selectin expression. EPC phenotype was characterized as the cells positive for the endothelial markers CD31/PECAM-1, KDR/VEGFR2 and CD146, but negative for the leukocyte markers CD45, CD14 or CD115.
For estimating the efficiency of cell transfection, 24 h after nucleofection, the green fluorescent protein (GFP) signal was assessed in MEG-01 cells and platelets without or with co-transfection of a GFP-expressing plasmid (pmaxGFP TM Vector; Lonza, Basel, Switzerland).
Argonaute 2 immunoprecipitation (Ago2 IP)
Washed platelets were treated with vehicle or thrombin (0.1 U mL
À1
) for 30 min at 37°C, followed by UV crosslinking (150 mJ cm
À2
; Stratalinker Ò UV Crosslinker 2400; Stratagene Inc., La Jolla, CA, USA). Platelets were then centrifuged, and platelet pellets were lysed with NP40 lysis buffer (Invitrogen) supplemented with 1 mM PMSF (Sigma), 1% proteinase inhibitor cocktail (Sigma), 1 mM dithiothreitol (DTT; Invitrogen) and 200 U mL
À1
RNase OUT (Invitrogen). The lysates were centrifuged at 17 000 9 g for 30 min at 4°C, and the supernatant was collected. The samples were then incubated with Dynabeads Ò Protein G (10007D; Invitrogen) coupled to anti-Ago2 or the isotypic control IgG for 4 h at 4°C with rotation. Thereafter, the beads were washed five times using the NT2 washing buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM MgCl 2 , 0.05% NP40) at 4°C with rotation. The success of Ago2-IP was confirmed by western blotting. The washed beads were then treated with proteinase K (1 mg mL
) supplemented with 1% sodium dodecyl sulfalte (SDS) at 55°C for 1 h with shaking every 5-10 min. After protein digestion, the suspension of proteinase K-treated beads was placed on a magnetic separator, and the supernatant was collected for RNA extraction.
RNA extraction
RNA extraction of the whole cell lysate of platelets and Ago2-IP supernatant was carried out using TRIzol reagent (Invitrogen) and according to the manufacturer's instructions. RNA concentrations were determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
Microarray-based miRNA Profiling miRNA expression profiling was performed using Agilent' Human miRNA Microarray System (Agilent, Santa Clara, CA, USA). The assay is based on a highly efficient labeling method linked to the microarray probe design strategy, resulting in highly specific detection of mature miRNAs. In brief, RNA (100 ng) of unstimulated and thrombin-stimulated platelets from the same donor was fluorescencelabeled with Cyanine 3-pCp, and hybridized with the arrays for 20 h at 55°C. Slides were scanned in an Agilent microarray scanner G2565BA, and obtained images were processed with the Feature Extraction Software 9.5.3.1. All data were normalized, log transformed and median centered. Only normalized miRNAs with less than 50% missing values across the samples were included in the further analysis, to avoid exclusion of miRNAs expressed only in either the resting or thrombin-stimulated condition. Hierarchical clustering of the samples was performed using the Cluster 3.0 software (http://bonsai.hgc.jp/~mde hoon/software/cluster/software.htm) and visualized with Java TreeView version 1.1.3 (http://jtreeview.sourceforge. net). Significance analysis of microarrays (SAM; https:// github.com/MikeJSeo/SAM) was performed to determine the differentially expressed miRNAs between two experimental groups using Wilcoxon statistics.
Reverse transcription-quantitative PCR (RT-qPCR)
miRNA cDNA was prepared using the TaqMan micro-RNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). Predesigned TaqMan microRNA assays for miR-27b, miR-130b and RNU6B were performed using an Applied Biosystems 7500 Fast Real-Time PCR System. All reactions were run in triplicates and in three independent experiments. For the total platelet miRNAs of whole cell lysates, the data were normalized to the expression of RNU6B. For quantification of Ago2-associated miRNAs, miR-130b was used as the endogenous control for normalization, based on its association with Ago2 complexes and constant expression in resting and stimulated platelets. Relative expressions were determined with the MC T method and reported as 2 ÀMMCT . mRNA cDNA was synthesized using random primers, and SYBR Ò Green-based detection was performed for TSP-1 mRNA quantification, using a pair of specific primers (R: ATGGGGACGTCCAACTCAGC, F: ACCG CATTCCAGAGTCTGGC; Invitrogen). All reactions were carried out in triplicates. The data were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and reported as 2
ÀMMCT
.
MEG-01 cell transfection
MEG-01 cells (American Type Tissue Culture/ATCC; Manassas, VA, USA) were cultured in RPMI1640 with 10% FBS. Before transfection, MEG-01 cells were subcultured for 2 to 3 days at 1-1.7 9 10 5 cells mL
À1
. MEG-01 cells (1 9 10 6 ) were transfected with 100 nM miR-27b-3p mimics or its corresponding negative control using the Amaxa Ò Cell Line Nucleofector Ò Kit C and Nucleofector Ò Device (Lonza) as per the manufacturer's instructions. The cells were collected 72 h after transfection, and then lysed with NP40 lysis buffer for western blotting analysis of TSP-1 protein levels. Transfection efficiency of MEG-01 cells was estimated by co-transfection of a GFPexpressing plasmid (pmaxGFP Ò Vector; Lonza). Flow cytometric analysis of GFP-expressing transfected MEG-01 cells was performed 24 h after the transfection.
Platelet transfection
Platelet transfection was performed using a modified protocol originally developed by P. Gresele and M. Malvestiti (http://www.google.com/patents/WO2014118817A2? cl=en). Briefly, RiboJuice Ò (32 lL) and basal culture medium (168 lL) were mixed to constitute the transfection medium for each reaction. Afterwards, miR-27b mimic or the negative control was added to the transfection medium at 200 nM. The mixture was incubated for 15 min at 22°C, transferred into the 1-ml aliquots of platelet suspension (5 9 10 8 mL À1 ), and then incubated for 10 min at 37°C. To remove the transfection reagents, PGI 2 (1 lM) was added, and the samples were centrifuged at 1000 9 g for 10 min. The supernatant was thoroughly removed , and platelet pellets were re-suspended with 1 mL basal culture medium. The transfected and untransfected platelets were stimulated with thrombin (0.1 U mL À1 ) and cultured at 37°C for 24 h. The samples were centrifuged twice at 3000 9 g for 10 min, and the pellets were stored at À80°C for further use.
Western blotting analysis
Protein lysates were prepared using NP-40 lysis buffer. Target proteins were probed with anti-Ago2/eIF2C2 (ab57113; Abcam), anti-TSP-1 (AF3074; R&D Systems) or anti-b-actin antibodies overnight at 4°C. After washing, anti-mouse IgG-HRP antibody (554002; BD Biosciences) or anti-goat IgG-HRP (HAF019; R&D Systems) was used as the secondary antibody. Detection was performed using the Novex ECL HRP chemiluminescent substrate reagent (WP20005; Invitrogen). Signals were visualized on Fujifilm LAS 4000 (Tokyo, Japan), and protein levels of the immunoblottings were quantified by ImageJ (NIH, Bethesda, MD, USA).
In vitro tube formation assay
To demonstrate if miR-27b transfection could affect the platelet angiogenic activities, in vitro tube formation was performed using platelet total lysates. The transfected platelets (2 9 10 9 mL
À1
) were cultured at 37°C for 24 h with thrombin (0.1 U mL À1 ) stimulation. At the end of platelet culture, the samples were spun, the supernatants were discarded, and platelets were re-suspended with the same volume of basic culture medium. The platelet total lysates were prepared by three freeze-and-thaw cycles. The tube formation assay was performed using the matrigel-coated l-Plate Angiogenesis 96 Well (Ibidi, Martinsried, Germany). Briefly, matrigel (Corning Inc., Tewksbury, MA, USA) was thawed at 4°C overnight. Matrigel solution (10 lL) was added to each well, and the plate was then incubated at 37°C for 1 h to allow matrigel solidification. EPC suspension (1.1 9 10 5 mL
; 70 lL; containing 10% platelet total lysate) was added to each matrigel-coated well and incubated at 37°C for 6 h. The tube formation was inspected under an inverted light microscope (40 9) and quantified using the Wimasis software (Munich, Germany).
Data presentation and statistics
Data are presented as mean AE SEMs. Comparisons were performed with Student's paired t-test using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). P < 0.05 was considered as significant.
Results
Thrombin stimulation altered platelet miRNA expression profiles
Thrombin stimulation (0.1 U mL À1 , 30 min, 37°C) evoked marked platelet activation. Flow cytometric analyses showed that single platelet counts were decreased by approximately 80%, representing a platelet aggregation rate of 80%, and that P-selectin-positive platelets among the remaining single platelets of thrombin-stimulated samples were elevated from about 10% in untreated platelets to 80-90% (Fig. 1B) .
To elucidate if platelet activation alters miRNA expression, we first performed miRNA expression microarray in the total RNAs isolated from platelets with and without thrombin stimulation (Fig. 1A) . We performed unsupervised clustering of 374-filtered miRNAs using Spearman rank correlation and complete linkage. The analyses revealed that the miRNA expression pattern of resting platelets was distinct from that of thrombin-stimulated platelets (Fig. 1D, left panel) . To identify altered miRNAs associated with thrombin stimulation, we performed SAM analyses between resting (unstimulated) and thrombin-stimulated platelets. We found that 208 miRNAs were elevated, whereas 166 miRNAs were decreased in thrombin-stimulated platelets (Fig. 1E and Table S1), with the q-value (FDR) of 30% as the cut off.
Ago2-associated miRNA profile in thrombin-stimulated platelets
To demonstrate whether thrombin stimulation also alters the miRNAs bound to Argonaute2 protein within the miRNA-induced silencing complex (miRISC), we pulled down Ago2-associated miRNAs of resting and thrombinstimulated samples using an Ago2 immunoprecipitation approach (Fig. 1A) . The efficiency of Ago2 immunoprecipitation was validated by immunoblotting (Fig. 1C) . Using unsupervised clustering, the thrombin-stimulated platelets were grouped together but separated from the resting platelets (Fig. 1D, right panel) , suggesting distinct miRNA expression profiles between the two conditions. SAM ; n = 3) were treated with vehicle (unstimulated/resting, R) or 0.1 U mL À1 thrombin (T) for 30 min at 37°C. Platelets were then spun down, and platelet pellets were lysed with NP-40 lysis buffer supplemented with 1 mM PMSF, 1% proteinase inhibitor cocktail, 1 mM DTT and 200 U mL À1 RNase OUT.
RNA was extracted from the whole cell lysates of platelets or from the product of Ago2 immunoprecipitation using the Trizol method. miRNA expression profiling was performed using Agilent's Human miRNA Microarray System (panel A). Platelet activation status at basal (red curve) and after thrombin stimulation (blue curve) was monitored by flow cytometric measurement of platelet P-selectin expression (panel B). Ago2-immunoprecipitation was verified by Ago2-western blotting (panel C). Hierarchical clustering of the samples based on miRNA expression was performed using the Cluster 3.0 software, and was visualized with Java TreeView version 1.1.3. One array from the total miRNAs and one from Ago2-associated miRNAs was excluded because of poor quality. The remaining samples were clustered based on the normalized miRNAs with less than 50% missing values across the samples using Spearman rank correlation and complete linkage. Their heat maps of the total miRNAs and Ago2-associated miRNAs from resting and thrombin-stimulated platelets are shown (panel D). Thrombin stimulation resulted in a number of up-or down-regulated miRNAs in both the total platelet and Ago2-associated miRNA repertoire (panel E). [Color figure can be viewed at wileyonlinelibrary.com] analyses, with the q-value (FDR) less than 30% set as the cut-off, showed that 73 miRNAs were up-regulated and that 30 miRNAs were down-regulated in thrombin-stimulated platelets, as compared with resting platelets (Fig. 1E and Table S2 ). Among the altered miRNAs in thrombinstimulated platelets, 34 miRNAs were found to be up-regulated both in the total and in Ago2-associated miRNAs, and seven miRNAs were down-regulated both in the total and in Ago2-associated miRNAs ( Fig. 1E and Table 1 ). Of note, miR-27b was an miRNA that was down-regulated by thrombin stimulation in both the total and Ago2-associated miRNAs. Our further work was focused on miR27b, as it has been shown to regulate protein synthesis of thrombospondin-1 [22] .
Down-regulated platelet miR-27b expression after thrombin stimulation
To verify the reductions of miR-27b levels seen in microarray analyses, RT-qPCR was performed to measure the expression levels of miR-27b in platelets with and without thrombin stimulation. In agreement with the microarray results, Fig. 2 shows that the expression levels Table 1 Synchronized miRNA alterations in the total platelet and Ago2-associated miRNAs upon thrombin stimulation in vitro
Higher expression
Lower expression let-7b-5p miR-151a-3p miR-222-3p miR-486-5p miR-27b-3p let-7c miR-16-5p miR-223-3p miR-625-5p miR-143-3p let-7f-5p miR-148b-3p miR-22-3p miR-638 miR-148a-3p let-7i miR-17-5p miR-23a-3p miR-652-3p miR-152 miR-125a-5p miR-181a-5p miR-25-3p miR-766-3p miR-17-3p miR-130b-3p miR-181b-5p miR-26b-5p miR-92a-3p miR-425-5p miR-142-3p miR-185-5p miR-30d-5p miR-93-5p miR-454-3p miR-142-5p miR-197-3p miR-320a miR-148b-3p miR-21-5p miR-339-5p RNAs were extracted using Trizol reagents (Invitrogen) from whole cell lysates (Total) or using Ago2 immunoprecipitation products (Ago2) from resting (open bars) and 0.1 U mL À1 thrombin-stimulated platelets (solid bars). The cDNA of miR-27b was prepared using the TaqMan MicroRNA Reverse Transcription Kit. For the total platelet miRNAs of whole cell lysates, the data were normalized to the expression of RNU6B. For quantifying Ago2-associated miRNAs, miR-130b was used as the endogenous control for normalization. Relative expressions were determined with the MCT method and reported as 2 ÀMMCT .
Data presented are from three independent experiments. *P < 0.05, ***P < 0.001, compared with corresponding resting samples.
Resting
Unstim. Unstim. Thrombin-stim.
Thrombin-stim. Thrombin-stim. Thrombin-stim.
Thrombin-stim. Thrombin-stim. . Total RNAs were extracted from platelet lysates using Trizol methods. TSP-1 mRNA was quantified using SYBR Green-based qPCR. All reactions were carried out in triplicate. The data were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and reported as 2À MMCT (panel A; n = 3). In separate experiments, resting and thrombin-stimulated platelets were lysed after 30-min treatment, or after 2-h or 24-h culture. Platelet lysates were prepared using NP-40 lysis buffer (FNN0021; Thermo Fisher Scientific) supplemented with 1 mM of phenylmethanesulfonyl fluoride and protease inhibitors (both from Invitrogen). The protein concentrations of cell lysates were measured by using a BCA protein assay kit (23227; Pierce Biotechnology). The lysates containing the same amount of proteins were separated using NuPAGE TM Novex TM 4-12% Bis-Tris Protein Gels, and then transferred to nitrocellulose membranes (LC2001; Invitrogen). Novex Sharp Prestained Protein Standards (57318; Invitrogen) were used as molecular weight standards. Membranes were blocked with 5% non-fat milk in TBST (Tris-buffered saline containing 0.05% Tween 20) for 1 h at room temperature, followed by incubation with anti-TSP-1 (AF3074, R&D Systems) or anti-b-actin antibodies overnight at 4°C. Afterwards, anti-goat IgG-HRP (HAF019, R&D Systems) was used as the secondary antibody. Detection was performed using the Novex ECL HRP chemiluminescent substrate reagent (WP20005; Invitrogen). The result presented was the representative image of three independent experiments (panel B), and the relative intensity of protein expression/immunoblotting levels was quantified by ImageJ (panel C). *P < 0.05, **P < 0.01, # P < 0.05, as compared with resting platelets at 0 h. [Color figure can be viewed at wileyonlinelibrary.com] of miR-27b were significantly reduced after thrombin stimulation in both platelet total miRNAs and Ago2-associated miRNAs.
Up-regulation of TSP-1 mRNA and protein levels in thrombin-activated platelets It has been shown that platelet activation can evoke de novo protein synthesis of TSP-1 [9] , and that miR-27b can regulate TSP-1 protein synthesis in bone marrow-derived angiogenic cells (BMACs) [22] . Hence, we sought to investigate if miR-27b regulates TSP-1 synthesis in platelets. We first monitored the TSP-1 mRNA expression level upon thrombin stimulation. Using a pair of specific primers, we showed that thrombin stimulation significantly elevated levels of matured TSP-1 mRNA (Fig. 3A) .
We next monitored TSP-1 protein levels of thrombinstimulated platelets after overnight culture (Fig. 3B ). As compared with resting/unstimulated platelets, 30 min of thrombin stimulation markedly decreased the TSP-1 content of platelets, indicating a significant release of TSP-1 upon platelet activation. TSP-1 levels of thrombin-stimulated platelets remained unchanged after 2-h culture, implying little or no protein synthesis. In contrast, TSP-1 levels of thrombin-stimulated platelets were significantly increased after overnight culture, even to a level much higher than that of resting platelets. Overnight culture of resting platelets also elevated TSP-1 levels, probably as a result of spontaneous platelet activation by, for example, the small amount of thrombin generated during prolonged platelet cultures. When the intensities of TSP-1 immunoblotting bands were quantified, it was clear that thrombin stimulation decreased TSP-1 intensity at 30 min and 2 h. However, overnight culture of thrombin-stimulated platelets markedly elevated TSP-1 immunoblotting intensities, which were proportional to TSP-1 protein levels, by more than 4-fold, as compared with < 1-fold elevation of resting platelets. These western blotting results indicated that there was an intensive de novo protein synthesis of TSP-1 in platelets after thrombin stimulation.
miR-27b overexpression inhibited TSP-1 expression in MEG-01 cells
Our results have shown that miR-27b is associated with the platelet Ago2 complex, and that platelets can synthesize a large amount of TSP-1 upon thrombin stimulation. We thus hypothesized that platelet TSP-1 synthesis may be regulated by miR-27b. To verify our hypothesis, we transfected miR-27b mimics into the platelet precursor cell MEG-01 cells using a nucleofection kit. Using a novel cell transfection protocol specially designed for platelets (Patent WO2014118817A2 with modifications), mature platelets were successfully transfected. Figure 5(A) shows that no fluorescence was seen in untransfected platelets, whereas bright GFP/green fluorescence was seen in transfected platelets under a fluorescent microscope. Flow cytometric analyses showed that GFPpositive cells were seen in up to 55% of transfected platelets (Fig 5B) . Using western blotting, TSP-1 expression of platelets transfected with miRNA mimic negative control did not differ from that of untransfected platelets, whereas TSP-1 expression of miR-27b mimic-transfected platelets was significantly reduced (Fig. 5C and D) . The results suggest that miR-27b can inhibit TSP-1 protein synthesis in platelets.
miR-27b mimic transfection rescued angiogenic activities of thrombin-stimulated platelets As miR-27b mimic transfection inhibited de novo synthesis of the anti-angiogenic factor TSP1 in both MEG-01 cells and mature platelets, we further investigated if miR27b overexpression would result in changes of platelet angiogenic activity. Thus, we collected the pellets of resting platelets, thrombin-stimulated platelets and thrombinstimulated platelets transfected with miR-27b mimic or miRNA mimic control. Whole cell lysates of platelets were obtained by freezing-and-thawing cycles. EPC tube formation assay was performed on matrigel-coated plates. As seen in Fig. 6 , capillary-like tube formation of EPCs suspended in the basal medium was sparse (branch points at 21 AE 6 per view) in the absence of platelet lysates (panel A). In contrast, supplementation with 10% whole cell lysate of resting platelets, which means the presence of the full cargo of all platelet angiogenic factors, markedly enhanced tube formation of EPCs, with the branch points increased to 203 AE 11 (panel B). When supplemented with the lysate of thrombin-stimulated platelets (panel C), the branch point numbers of capillary networks were still significantly increased as compared with non-supplementation, but to a much lesser extent than when supplemented by the lysate of resting platelets. Supplementation with the platelet lysate of thrombin-stimulated platelets with miRNA mimic control transfection showed a similar enhancement to that of thrombinstimulated platelets (panel D). However, supplementation of the lysate of thrombin-stimulated platelets with miR27b transfection had a significantly stronger enhancement on EPC tube formation (panel E) as compared with supplementation of thrombin-stimulated platelet lysates (panel C), seen as the increase of the branch point numbers from 114 AE 19 with thrombin-stimulated platelet lysates to 165 AE 37. These results imply that miR-27b can rescue the stimulatory effects of EPC tube formation of thrombin-stimulated platelets through inhibiting de novo synthesis of anti-angiogenic TSP1. 
Discussion
The present study found that thrombin stimulation in vitro altered miRNA profiles in platelets, and identified that miR-27b was down-regulated in both the total and Ago2-associated miRNAs. We showed that thrombin stimulation evoked de novo protein synthesis of TSP-1, and that miR-27b mimic transfection inhibited TSP-1 protein synthesis in both the megakaryocyte cell line MEG-01 cells and mature platelets. Interestingly, miR27b overexpression potentiated angiogenic activities of thrombin-stimulated platelets by inhibiting de novo protein synthesis of anti-angiogenic TSP-1.
Platelets contain a number of miRNAs [11, 23] and are equipped with fully functional miRNA effector complexes, namely Dicer and Ago2 [14] . During the recent years, there have been continuous efforts to investigate the biomarker potentials of circulating miRNAs for platelet dysfunction and/or cardiovascular diseases [15, 24, 25] . Thus, platelet activation can change miRNA expression profiles [23] , although this is not shown in all studies [26] . Moreover, miRNA profiles are changed in patients with myocardial infarction [17, 24] , and platelet miRNAs are differentially expressed in hyperreactive and hyporeactive subjects [11] . In the present study, we sought to illustrate the impacts of platelet miRNAs on platelet function. We showed that miRNA profiles in both total platelet miRNAs and Ago2-associated miRNAs were altered in thrombin-stimulated platelets. Dicer and TARBP2-catalysed pre-miRNA maturation is known to account for the elevation of miRNA levels in activated platelets [14] . On the other hand, activated platelets undergo the release of miRNA-containing microvesicles and vesiclefree protein complexes [27] and active degradation of mature miRNAs [28] , leading to the down-regulation of some miRNAs. The up-and down-regulated Ago2-associated miRNAs are a clear sign that platelet miRNAs may have regulatory roles in platelets per se, and imply that platelet miRNAs are likely to influence protein synthesis of activated platelets.
Platelets can conduct signal-dependent protein syntheses [7, 29] . We and others have demonstrated that thrombin-stimulated platelets exert de novo protein synthesis of angiogenesis regulatory proteins PAI-1 [6] and SDF-1a [10] . Earlier reports have also shown that platelets can synthesize TSP-1 [9, 30] , and that platelets contain a high copy number of TSP-1 mRNAs [31] , implying that platelets may carry out efficient de novo protein synthesis of TSP-1. Platelet-derived TSP-1 is a critical inhibitor of angiogenesis [32, 33] , in which TSP-1 exerts anti-angiogenic effects by inhibiting migration and proliferation and inducing apoptosis of endothelial cells [34] , and inhibits angiogenesis in vitro and in vivo [33, 35] . Hence, we explored if platelet miRNAs could regulate platelet activation-induced de novo synthesis of TSP-1. We showed that thrombin stimulation induced a marked synthesis of TSP-1, to protein levels 4-5-fold higher than those in resting platelets. The newly synthesized TSP-1 may be partially sequestered intracellularly and partially released over time during the incubation, similar to the timesequential cytokine release of activated platelets [36] , and may have a major impact on platelet angiogenic activities.
Although platelets are rich in miRNAs, their roles in platelet biology are largely unexplored. We have identified in the present study that miR-27b was down-regulated in both total platelet and Ago2-associated miRNAs of thrombin-stimulated platelets. As miR-27b can regulate TSP-1 synthesis in bone marrow-derived angiogenic cells (BMACs) [22] , we hypothesized that platelet miR-27b may regulate TSP-1 de novo synthesis in activated platelets. Because platelets are resistant to transfection with an ordinary protocol [37] , we first employed the line MEG-01 cells to verify our hypothesis. Our results revealed that TSP-1 expression was decreased after miR-27b mimic transfection, indicating that miR-27b can interfere with TSP-1 synthesis. Using a newly developed technique designed for platelet transfection, we have successfully transfected human mature platelets. We showed that miR-27b mimic transfection hampered TSP-1 de novo synthesis of thrombin-stimulated platelets, in which miRNAs exert their inhibitory effects via interfering with mRNA translation and probably also via accelerating the decay of targeted mRNAs [38, 39] . Hence, our findings proved that platelet miRNAs can regulate their own protein synthesis. Even more importantly, our work demonstrated that miR-27b mimic transfection enhanced pro-angiogenic effects of thrombin-stimulated platelets on EPC tube formation. Collectively, our data suggest that thrombin stimulation evokes profound de novo synthesis of antiangiogenic factor TSP-1, which is a cooperative result of thrombin-induced TSP-1 mRNA maturation and thrombin-induced reduction of platelet miR-27b (a negative controller of TSP-1 synthesis). Therefore, miR-27b-regulated thrombin-stimulated de novo synthesis of anti-angiogenic TSP-1 represents a novel regulatory mechanism of platelet angiogenic activities. This mechanism constitutes a subtle regulation of platelet angiogenic activities, and should prevent overheated platelet-dependent angiogenesis. It should, however, be noted that the present work was carried out in vitro, and that the present findings may not fully recapitulate the situation in vivo.
In conclusion, platelet activation alters the platelet miRNA profile in both the total platelet and Ago2-associated miRNAs. Thrombin stimulation induces marked de novo synthesis of TSP-1 in platelets. The latter is a negative regulatory mechanism of platelet angiogenic activities, and is achieved by thrombin-induced TSP-1 miRNA translation and down-regulation of miR-27b.
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